|1.||Catalfo, Alfio: 5 articles (12/2010 - 09/2002)|
|2.||de Guidi, Guido: 3 articles (12/2010 - 09/2002)|
|3.||Belvedere, Alessandra: 3 articles (12/2010 - 09/2002)|
|4.||De Guidi, Guido: 2 articles (02/2007 - 03/2005)|
|5.||Renis, Marcella: 2 articles (02/2007 - 03/2005)|
|6.||Gu, Li-Yang: 1 article (08/2011)|
|7.||Lu, Hong: 1 article (08/2011)|
|8.||Lin, Wei-Wei: 1 article (08/2011)|
|9.||Ge, Zhi-Zheng: 1 article (08/2011)|
|10.||Li, Xiao-Bo: 1 article (08/2011)|
06/01/1992 - "The results indicate that Rufloxacin at the oral dose of 200 mg/die is well tolerated and effective in the treatment of complicated cystitis."
06/01/1992 - "Eighteen patients of either sex (14 M; 4 F), ranging in age from 23 to 79 years, with clinical diagnosis of complicated cystitis due to Rufloxacin sensitive pathogens, were enrolled. "
01/01/1995 - "A single oral dose of 400 mg of rufloxacin is as effective and safe as a single oral dose of 800 mg of pefloxacin for the treatment of acute uncomplicated cystitis in women."
02/01/1996 - "This study shows that single doses of rufloxacin are as effective as a norfloxacin 3-day standard treatment in uncomplicated cystitis. "
02/01/1996 - "The efficacy and safety of rufloxacin (400 mg, single dose) were compared to those of norfloxacin (400 mg twice a day for 3 days) for the treatment of women with uncomplicated cystitis. "
10/01/1991 - "Hence, a single daily dose of rufloxacin 200 mg appears to be a safe treatment for chronic bacterial prostatitis."
10/01/1991 - "In an open study, 27 patients with chronic bacterial prostatitis were treated for four weeks with rufloxacin. "
10/01/1991 - "An open multicentre study on the efficacy and safety of rufloxacin in patients with chronic bacterial prostatitis."
10/01/1991 - "The levels of rufloxacin found in prostate tissue and fluid, in this study, exceeded the MICs for most micro-organisms causing chronic bacterial prostatitis."
02/01/2010 - "[Qianlie Jiedu capsule combined with rufloxacin for chronic prostatitis: a randomized double-blind controlled clinical trial]."
12/01/1992 - "The present study shows that rufloxacin is not only very effective on both mouse strains, but can completely eradicate the salmonellae from livers and spleens when given early in the infection of CBA resistant mice."
10/01/1994 - "In-vivo models of experimental infections showed that prophylactic administration of rufloxacin increased the survival of mice after challenge with Candida albicans."
12/01/1993 - "The penetration of rufloxacin into sites of potential infection in the respiratory tract."
12/01/1993 - "The broad antibacterial spectrum of rufloxacin and its high and prolonged biliary concentrations suggest that this drug may be useful for treatment of biliary tract infections."
12/01/1992 - "Effects of rufloxacin in Salmonella typhimurium infection in mice."
|4.||Typhoid Fever (Typhoid)
|5.||Salmonella Infections (Salmonellosis)
12/01/1992 - "Innately susceptible BALB/c and resistant CBA mice were used to investigate the efficacy of rufloxacin in controlling systemic salmonella infections when given for brief or prolonged periods. "
12/01/1992 - "This study was undertaken to investigate the efficacy of rufloxacin, a new quinolone which is interesting due to its pharmacokinetics characterized by a long plasma half-life, in the treatment of systemic salmonella infections in the mouse typhoid model. "
|6.||Enoxacin (AT 2266)
|9.||DNA (Deoxyribonucleic Acid)